Dose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemia

This publication has 28 references indexed in Scilit:

• Five‐Year Real‐World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B‐Cell Precursor Acute Lymphoblastic Leukemia
  American Journal of Hematology, 2025
• Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions
  Cancer, 2024
• Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper
  Clinical Pharmacology & Therapeutics, 2024
• US Food and Drug Administration embraces using innovation to identify optimized dosages for patients with cancer
  CPT: Pharmacometrics & Systems Pharmacology, 2023
• Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates?
  Clinical Pharmacology & Therapeutics, 2021
• Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia
  Transplantation and Cellular Therapy, 2019
• Pharmacokinetic/Pharmacodynamic Modeling to Support the Re‐approval of Gemtuzumab Ozogamicin
  Clinical Pharmacology & Therapeutics, 2019
• Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study
  Cancer, 2019
• Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma
  Journal of Pharmacokinetics and Pharmacodynamics, 2019
• Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
  Cancer, 2013